The first FDA-approved gene therapies are living drugs: immune cells taken from cancer patients engineered to target tumor cells. However, for many patients, these advanced therapies do not result in a long-lasting remission. Now, scientists at the New York Genome Center and New York University have developed a genetic screening platform to identify genes that can enhance immune cells to make them more persistent and increase their ability to eradicate tumor cells.
Programming the immune system to supercharge cancer cell therapies
March 16, 2022
Related blog posts
New drug shows promise for fighting both COVID-19 and cancer
November 15, 2022